BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 23, 2025
Home » Topics » Briefs » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Deal handshake with graphic overlay

Diasorin unloads cytometry unit at a loss

Feb. 14, 2023
By Annette Boyle
Diasorin SpA sold its Flow Cytometry and Imaging (FCI) business unit to Cytek Biosciences Inc. for $46.5 million in cash. That’s quite a drop from the $75 million price Diasorin subsidiary Luminex Corp. paid Milleporesigma for the FCI assets in 2018. The companies expect the sale to close within 30 days.
Read More
Close-up of eye with digital focus

Frizzled sizzles as Surrozen nails down Boehringer deal worth almost $600M

Oct. 6, 2022
By Randy Osborne
Surrozen Inc.’s back-end-loaded deal with Boehringer Ingelheim GmbH for the preclinical frizzled class receptor 4 agonist SZN-413 takes aim at vascular function in retinal diseases. The arrangement brings an up-front payment to South San Francisco-based Surrozen of $12.5 million, plus up to $586.5 million in potential development, regulatory and commercial milestone rewards, along with mid-single-digit to low-double-digit royalties on sales. After an initial period of joint research, Boehringer, of Ingelheim, Germany, will take over development and commercial responsibilities.
Read More
Jean-Paul Ansel

Diagnostic Medical Systems spins out its medical imaging business

Nov. 29, 2021
By Bernard Banga
PARIS – Diagnostic Medical Systems SA (DMS) is spinning off its medical imaging division into Asit Biotech NV. This agreement, between two firms listed on the Euronext exchange, involves French med-tech company DMS merging its flourishing medical imaging business with the Belgian biopharmaceutical firm and acquiring a controlling stake in the company.
Read More
11-11-Diopsys.png

Lumithera envisions brighter future with Diopsys acquisition

Nov. 11, 2021
By Annette Boyle

Lumithera Inc. will acquire Diopsys Inc. for an undisclosed amount in an all-stock transaction expected to close in the next few months. The deal has been approved by shareholders of both companies. Together, they plan to form a theranostic company that can provide a continuum of care for patients with age-related macular degeneration and other degenerative ocular diseases or injury.


Read More
Chain links composed of binary code

Alivecor taps blockchain technology to connect Kardiamobile users with physicians

Oct. 27, 2021
By Catherine Longworth
Alivecor Inc. is partnering with blockchain technology company Solve.Care to connect users of its Kardiamobile device to physicians through a telehealth network. Tallinn, Estonia-based Solve.Care’s blockchain platform, the Global Telehealth Exchange (GTHE), is an open global cross-border telehealth network currently available in 27 countries. Alivecor’s Kardiamobile 6L device is the first and only six-lead personal ECG cleared by the FDA. Through the partnership, Kardiamobile devices will be integrated with GTHE where physicians will be able to access a user’s electrocardiogram (ECG) reading upon their consent through teleconsultations.
Read More
Gold wireframe handshake

Everly Health seals third acquisition of the year with women’s health startup Natalist

Oct. 21, 2021
By Catherine Longworth
The parent company of digital health unicorn Everlywell Inc. is expanding its portfolio of women’s health products through the acquisition of Charleston, S.C.-based startup Natalist Inc. The purchase marks Everly Health’s third acquisition of the year following agreements to buy national clinician network PWN Health and home lab testing company Home Access Health Corp. Financial terms of all deals were not disclosed. Headquartered in Austin, Texas, Everly Health will add Natalist’s suite of reproductive products to its existing tests for menopause, fertility hormones and sexual health.
Read More
Handshake, businessmen holding dollar sign, lightbulb

Titan takes off with $10M Medtronic license payment

June 15, 2021
By David Godkin
TORONTO – Titan Medical Inc. has received a $10 million license payment from Medtronic plc for a total of $30 million that the Irish med-tech firm has invested in robotic-assisted surgical technologies developed by Titan. Titan is pursuing gynecologic surgical applications for its Enos robotic single access surgical system, licensing it and related intellectual property to Medtronic while retaining worldwide rights to commercialize technologies for use with the Enos system.
Read More
Nonprofit stamp

Biopharma nonprofit/grant deals triple that of 2019

Nov. 25, 2020
By Karen Carey
The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019.
Read More

Daily M&A

Sep. 30, 2019

Daily M&A

Sep. 27, 2019
Previous 1 2 3 4 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing